Trial Profile
Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients With MYC Alterations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Apr 2022
Price :
$35
*
At a glance
- Drugs Fimepinostat (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Curis
- 25 Apr 2022 Number of treatment arms increased from 1 to 3. Trial design was amended (parallel & randomized assigned).
- 30 Aug 2019 Status changed from active, no longer recruiting to completed.
- 17 Aug 2019 This trial has been completed in Germany, according to European Clinical Trials Database record